Drugs & Aging

, Volume 29, Issue 5, pp 359–376

Medication-Related Falls in the Elderly

Causative Factors and Preventive Strategies
  • Allen R. Huang
  • Louise Mallet
  • Christian M. Rochefort
  • Tewodros Eguale
  • David L. Buckeridge
  • Robyn Tamblyn
Review Article

Abstract

People are living to older age. Falls constitute a leading cause of injuries, hospitalization and deaths among the elderly. Older people fall more often for a variety of reasons: alterations in physiology and physical functioning, and the use (and misuse) of medications needed to manage their multiple conditions. Pharmacological factors that place the elderly at greater risk of drug-related side effects include changes in body composition, serum albumin, total body water, and hepatic and renal functioning. Drug use is one of the most modifiable risk factors for falls and falls-related injuries. Fall-risk increasing drugs (FRIDs) include drugs for cardiovascular diseases (such as digoxin, type 1a anti-arrhythmics and diuretics), benzodiazepines, antidepressants, antiepileptics, antipsychotics, antiparkinsonian drugs, opioids and urological spasmolytics. Psychotropic and benzodiazepine drug use is most consistently associated with falls. Despite the promise of a more favourable side-effect profile, evidence shows that atypical antipsychotic medications and selective serotonin reuptake inhibitor antidepressants do not reduce the risk of falls and hip fractures. Despite multiple efforts with regards to managing medication-associated falls, there is no clear evidence for an effective intervention. Stopping or lowering the dose of psychotropic drugs and benzodiazepines does work, but ensuring a patient remains off these drugs is a challenge. Computer-assisted alerts coupled with electronic prescribing tools are a promising approach to lowering the risk of falls as the use of information technologies expands within healthcare.

References

  1. 1.
    World Health organization (WHO). World Health Statistics 2011. Geneva: WHO Press, 2011Google Scholar
  2. 2.
    Hoyert DL, Kochanek KD, Murphy SL. Deaths: final data for 1997. Natl Vital Stat Rep 1999; 47 (19): 1–104Google Scholar
  3. 3.
    Tinetti ME, Baker DI, McAvay G, et al. A multifactorial intervention to reduce the risk of falling among elderly people living in the community. N Engl J Med 1994; 331 (13): 821–7PubMedGoogle Scholar
  4. 4.
    Hanlon JT, Landerman LR, Fillenbaum GG, et al. Falls in African American and White community-dwelling elderly residents. J Gerontol A Biol Sci Med Sci 2002; 57 (7): M473–8PubMedGoogle Scholar
  5. 5.
    Zecevic AA, Salmoni AW, Speechley M, et al. Defining a fall and reasons for falling: comparisons among the views of seniors, health care providers, and the research literature. Gerontologist 2006; 46 (3): 367–76PubMedGoogle Scholar
  6. 6.
    Violence and injury prevention: other injury topics: falls. Geneva: WHO [online]. Available from URL: http://www.who.int/violence_injury_prevention/other_injury/falls/en/index.html [Accessed 2012 Mar 26]
  7. 7.
    Crentsil V, Ricks MO, Xue QL, et al. A pharmacoepidemiologic study of community-dwelling, disabled older women: factors associated with medication use. Am J Geriatr Pharmac 2010; 8 (3): 215–24Google Scholar
  8. 8.
    Bjerrum L, Rosholm JU, Hallas J, et al. Methods for estimating the occurrence of polypharmacy by means of a prescription database. Eur J Clin Pharmacol 1997; 53 (1): 7–11PubMedGoogle Scholar
  9. 9.
    Tamblyn R, Huang A, Perreault R, et al. The medical office of the 21st century (MOXXI): effectiveness of computerized decision-making support in reducing inappropriate prescribing in primary care. Can Med Assoc J 2003; 169 (6): 549–56Google Scholar
  10. 10.
    Vestal RE. Aging and pharmacology. Cancer 1997; 80 (7): 1302–10PubMedGoogle Scholar
  11. 11.
    Hammerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly: clinical implications. Clin Pharmacokinet 1998; 35 (1): 49–64PubMedGoogle Scholar
  12. 12.
    Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 2003; 38 (8): 843–53PubMedGoogle Scholar
  13. 13.
    Campion EW, Avorn J, Reder VA, et al. Overmedication of the low-weight elderly. Arch Intern Med 1987; 147 (5): 945–7PubMedGoogle Scholar
  14. 14.
    Cusack BJ. Pharmacokinetics in older persons. Am J Geriatr Pharmac 2004; 2 (4): 274–302Google Scholar
  15. 15.
    Grenier L. Pharmacocinétique et pharmacodynamie. In: Mallet L, Grenier L, Guimond J, et al., editors. Manuel de soins pharmaceutiques en gériatrie. Quebec (QC): Les presses de l université Laval, 2003: 77–98Google Scholar
  16. 16.
    Hutchison LC, O’Brien CE. Changes in pharmacokinetics and pharmacodynamics in the elderly patient. J Pharm Pract 2007; 20(1): 4–12Google Scholar
  17. 17.
    Kinirons MT, O’Mahony MS. Drug metabolism and ageing. Br J Clin Pharmacol 2004; 57 (5): 540–4PubMedGoogle Scholar
  18. 18.
    Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet 2007; 370 (9582): 185–91PubMedGoogle Scholar
  19. 19.
    Campbell N, Boustani M, Limbil T, et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging 2009; 4: 225–33PubMedGoogle Scholar
  20. 20.
    Minzenberg MJ, Poole JH, Benton C, et al. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiat 2004; 161 (1): 116–24PubMedGoogle Scholar
  21. 21.
    Landi F, Russo A, Liperoti R, et al. Anticholinergic drugs and physical function among frail elderly population. Clin Pharmacol Ther 2006; 81 (2): 235–41PubMedGoogle Scholar
  22. 22.
    Cao YJ, Mager DE, Simonsick EM, et al. Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women. Clin Pharmacol Ther 2007; 83 (3): 422–9PubMedGoogle Scholar
  23. 23.
    Hilmer SN, Mager DE, Simonsick EM, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med 2007; 167 (8): 781–7PubMedGoogle Scholar
  24. 24.
    Wilson NM, Hilmer SN, March LM, et al. Associations between drug burden index and falls in older people in residential aged care. J Am Geriatr Soc 2011; 59 (5): 875–80PubMedGoogle Scholar
  25. 25.
    Aizenberg D, Sigler M, Weizman A, et al. Anticholinergic burden and the risk of falls among elderly psychiatric inpatients: a 4-year case-control study. Int Psychogeriatr 2002; 14 (03): 307–10PubMedGoogle Scholar
  26. 26.
    Boss GR, Seegmiller JE. Age-related physiological changes and their clinical significance. Western J Med 1981; 135 (6): 434–40Google Scholar
  27. 27.
    Dalstra JAA, Kunst AE, Borrell C, et al. Socioeconomic differences in the prevalence of common chronic diseases: an overview of eight European countries. Int J Epidemiol 2005; 34 (2): 316–26PubMedGoogle Scholar
  28. 28.
    Hogan DB, Ebly EM, Fung TS. Disease, disability, and age in cognitively intact seniors: results from the Canadian Study of Health and Aging. J Gerontol A Biol Sci Med Sci 1999; 54 (2): M77–82PubMedGoogle Scholar
  29. 29.
    Jemal A, Ward E, Hao Y, et al. Trends in the leading causes of death in the United States, 1970–2002. JAMA 2005; 294 (10): 1255–9PubMedGoogle Scholar
  30. 30.
    Scuffham P, Chaplin S, Legood R. Incidence and costs of unintentional falls in older people in the United Kingdom. J Epidemiol Commun H 2003; 57 (9): 740–4Google Scholar
  31. 31.
    Public health and aging: nonfatal injuries among older adults treated in hospital emergency department: United States, 2001. MMWR Morb Mortal Wkly Rep 2003; 52 (42): 1019–22Google Scholar
  32. 32.
    Rubenstein LZ, Josephson KR. The epidemiology of falls and syncope. Clin Geriatr Med 2002; 18 (2): 141–58PubMedGoogle Scholar
  33. 33.
    Tinetti ME, Doucette J, Claus E, et al. Risk factors for serious injury during falls by older persons in the community. J Am Geriatr Soc 1995; 43 (11): 1214–21PubMedGoogle Scholar
  34. 34.
    Tinetti ME, Williams CS. Falls, injuries due to falls, and the risk of admission to a nursing home. N Engl J Med 1997; 337 (18): 1279–84PubMedGoogle Scholar
  35. 35.
    Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. JAMA 1995; 274 (1): 29–34PubMedGoogle Scholar
  36. 36.
    Baker GR, Norton PG, Flintoft V, et al. The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada. Can Med Assoc J 2004; 170 (11): 1678–86Google Scholar
  37. 37.
    King MB, Tinetti ME. Falls in community-dwelling older persons. J Am Geriatr Soc 1995; 43 (10): 1146–54PubMedGoogle Scholar
  38. 38.
    Hosseini H, Hosseini N. Epidemiology and prevention of fall injuries among the elderly. Hosp Top 2008; 86 (3): 15–20PubMedGoogle Scholar
  39. 39.
    Guelich MM. Prevention of falls in the elderly: a literature review. Top Geriatr Rehabil 1999; 15 (1): 15–25Google Scholar
  40. 40.
    Van der Velde N, Stricker BH, Pols HA, et al. Risk of falls after withdrawal of fall-risk-increasing drugs: a prospective cohort study. Br J Clin Pharmacol 2007; 63 (2): 232–7PubMedGoogle Scholar
  41. 41.
    Kragh A, Elmstahl S, Atroshi I. Older adults’ medication use 6 months before and after hip fracture: a population-based cohort study. J Am Geriatr Soc 2011; 59 (5): 863–8PubMedGoogle Scholar
  42. 42.
    Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: II. Cardiac and analgesic drugs. J Am Geriatr Soc 1999; 47 (1): 40–50PubMedGoogle Scholar
  43. 43.
    Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 1999; 47 (1): 30–9PubMedGoogle Scholar
  44. 44.
    Woolcott JC, Richardson KJ, Wiens MO, et al. Metaanalysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 2009; 169 (21): 1952–60PubMedGoogle Scholar
  45. 45.
    Bloch F, Thibaud M, Dugue B, et al. Psychotropic drugs and falls in the elderly people: updated literature review and meta-analysis. J Aging Health 2011; 23 (2): 329–46PubMedGoogle Scholar
  46. 46.
    Liu B, Anderson G, Mittmann N, et al. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998; 351 (9112): 1303–7PubMedGoogle Scholar
  47. 47.
    Nurminen J, Puustinen J, Piirtola M, et al. Psychotropic drugs and the risk of fractures in old age: a prospective population-based study. BMC Public Health 2010; 10: 396. doi:10.1186/1471-2458-10–396PubMedGoogle Scholar
  48. 48.
    Moden B, Merlo J, Ohlsson H, et al. Psychotropic drugs and falling accidents among the elderly: a nested case control study in the whole population of Scania, Sweden. J Epidemiol Commun H 2010; 64 (5): 440–6Google Scholar
  49. 49.
    Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007; 146 (11): 775–86PubMedGoogle Scholar
  50. 50.
    Vitry AI, Hoile AP, Gilbert AL, et al. The risk of falls and fractures associated with persistent use of psychotropic medications in elderly people. Arch Gerontol Geriatr 2010; 50 (3): e1–4PubMedGoogle Scholar
  51. 51.
    Sullivan MD, Edlund MJ, Fan MY, et al. Trends in use of opioids for non-cancer pain conditions 2000–2005 in commercial and Medicaid insurance plans: the TROUP study. Pain 2008; 138 (2): 440–9PubMedGoogle Scholar
  52. 52.
    Holbrook AM, Crowther R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. Can Med Assoc J 2000; 162 (2): 225–33Google Scholar
  53. 53.
    Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with the use of morphine and opiates. J Intern Med 2006; 260 (1): 76–87PubMedGoogle Scholar
  54. 54.
    Ensrud KE, Blackwell TL, Mangione CM, et al. Central nervous system-active medications and risk for falls in older women. J Am Geriatr Soc 2002; 50 (10): 1629–37PubMedGoogle Scholar
  55. 55.
    Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989; 262 (23): 3303–7PubMedGoogle Scholar
  56. 56.
    Passaro A, Volpato S, Romagnoni F, et al. Benzodiazepines with different half-life and falling in a hospitalized population: the GIFA study. Gruppo Italiano di Farmacovigilanza nell’Anziano. J Clin Epidemiol 2000; 53 (12): 1222–9PubMedGoogle Scholar
  57. 57.
    Herings RMC, Stricker BHC, De BA, et al. Benzodiazepines and the risk of falling leading to femur fractures: dosage more important than elimination half-life. Arch Intern Med 1995; 155 (16): 1801–7PubMedGoogle Scholar
  58. 58.
    Ray WA, Thapa PB, Gideon P. Benzodiazepines and the risk of falls in nursing residents home. J Am Geriatr Soc 2000; 48 (6): 682–5PubMedGoogle Scholar
  59. 59.
    Neutel CI, Perry S, Maxwell C. Medication use and risk of falls. Pharmacoepidemiol Drug Saf 2002; 11 (2): 97–104PubMedGoogle Scholar
  60. 60.
    Tamblyn R, Abrahamowicz M, Du BR, et al. A 5-year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users. J Am Geriatr Soc 2005; 53 (2): 233–41PubMedGoogle Scholar
  61. 61.
    Gauthier S, Cummings J, Ballard C, et al. Management of behavioral problems in Alzheimer’s disease. Int Psychogeriatr 2010; 22 (3): 346–72PubMedGoogle Scholar
  62. 62.
    Hien le TT, Cumming RG, Cameron ID, et al. Atypical antipsychotic medications and risk of falls in residents of aged care facilities. J Am Geriatr Soc 2005; 53 (8): 1290–5Google Scholar
  63. 63.
    Mehta S, Chen H, Johnson ML, et al. Risk of falls and fractures in older adults using antipsychotic agents: a propensity-matched retrospective cohort study. Drugs Aging 2010; 27 (10): 815–29PubMedGoogle Scholar
  64. 64.
    Liperoti R, Onder G, Lapane KL, et al. Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case-control study. J Clin Psychiat 2007; 68 (6): 929–34Google Scholar
  65. 65.
    Thapa PB, Gideon P, Cost TW, et al. Antidepressants and the risk of falls among nursing home residents. N Engl J Med 1998; 339 (13): 875–82PubMedGoogle Scholar
  66. 66.
    Arfken CL, Wilson JG, Aronson SM. Retrospective review of selective serotonin reuptake inhibitors and falling in older nursing home residents. Int Psychogeriatr 2001; 13 (1): 86–91Google Scholar
  67. 67.
    Coupland C, Dhiman P, Morriss R, et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. Br Med J 2011 Aug 2; 343: d4551. doi:10.1136/bmj.d4551Google Scholar
  68. 68.
    Mallet L. Les anticonvulsivants. In: Mallet L, Grenier L, Guimond J, et al., editors. Quebec (QC): Les Presses de l université Laval, 2003: 223–44Google Scholar
  69. 69.
    Kelly KD, Pickett W, Yiannakoulas N, et al. Medication use and falls in community-dwelling older persons. Age Ageing 2003; 32 (5): 503–9PubMedGoogle Scholar
  70. 70.
    Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with parkinsonism and anti-Parkinson drugs. Calcified Tissue Int 2007; 81 (3): 153–61Google Scholar
  71. 71.
    Kim DH, Brown RT, Ding EL, et al. Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials. J Am Geriatr Soc 2011; 59 (6): 1019–31PubMedGoogle Scholar
  72. 72.
    Takkouche B, Montes-Martinez A, Gill SS, et al. Psychotropic medications and the risk of fracture: a meta-analysis. Drug Saf 2007; 30 (2): 171–84PubMedGoogle Scholar
  73. 73.
    Guo Z, Wills P, Viitanen M, et al. Cognitive impairment, drug use, and the risk of hip fracture in persons over 75 years old: a community-based prospective study. Am J Epidemiol 1998; 148 (9): 887–92PubMedGoogle Scholar
  74. 74.
    Ensrud KE, Blackwell T, Mangione CM, et al. Central nervous system active medications and risk for fractures in older women. Arch Intern Med 2003; 163 (8): 949–57PubMedGoogle Scholar
  75. 75.
    Hanlon JT, Boudreau RM, Roumani YF, et al. Number and dosage of central nervous system medications on recurrent falls in community elders: the Health, Aging and Body Composition study. J Gerontol A Biol Sci Med Sci 2009; 64 (4): 492–8PubMedGoogle Scholar
  76. 76.
    Buckeridge D, Huang A, Hanley J, et al. Risk of Injury associated with opioid use in older adults. J Am Geriatr Soc 2010; 58 (9): 1664–70PubMedGoogle Scholar
  77. 77.
    Koski K, Luukinen H, Laippala P, et al. Physiological factors and medications as predictors of injurious falls by elderly people: a prospective population-based study. Age Ageing 1996; 25 (1): 29–38PubMedGoogle Scholar
  78. 78.
    Nelson JM, Dufraux K, Cook PF. The relationship between glycemic control and falls in older adults. J Am Geriatr Soc 2007; 55 (12): 2041–4PubMedGoogle Scholar
  79. 79.
    Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358 (24): 2545–59Google Scholar
  80. 80.
    Malmivaara A, Heliovaara M, Knekt P, et al. Risk factors for injurious falls leading to hospitalization or death in a cohort of 19,500 adults. Am J Epidemiol 1993; 138 (6): 384–94PubMedGoogle Scholar
  81. 81.
    Kurzthaler I, Wambacher M, Golser K, et al. Alcohol and benzodiazepines in falls: an epidemiological view. Drug Alcohol Depen 2005; 79 (2): 225–30Google Scholar
  82. 82.
    Onen SH, Onen F, Mangeon JP, et al. Alcohol abuse and dependence in elderly emergency department patients. Arch Gerontol Geriat 2005; 41 (2): 191–200Google Scholar
  83. 83.
    Baker SP, Haddon Jr W. Reducing injuries and their results: the scientific approach. Milbank Q 1974; 52 (4): 377–89Google Scholar
  84. 84.
    Haddon J. Options for the prevention of motor vehicle crash injury. Israel J Med Sci 1980; 16 (1): 45–65PubMedGoogle Scholar
  85. 85.
    Haddon Jr W. On the escape of tigers: an ecologic note. Am J Public Health N 1970; 60 (12): 2229–34Google Scholar
  86. 86.
    Runyan CW. Using the Haddon matrix: introducing the third dimension. Injury Prev 1998; 4 (4): 302–7Google Scholar
  87. 87.
    Beers MH, Ouslander JG, Rollingher I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents. Arch Intern Med 1991; 151 (9): 1825–32PubMedGoogle Scholar
  88. 88.
    Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med 1997; 157 (14): 1531–6PubMedGoogle Scholar
  89. 89.
    Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003; 163 (22): 2716–24PubMedGoogle Scholar
  90. 90.
    McLeod PJ, Huang AR, Tamblyn RM, et al. Defining inappropriate practices in prescribing for elderly people: a national consensus panel. Can Med Assoc J 1997; 156 (3): 385–91Google Scholar
  91. 91.
    The American Geriatrics Society. American geriatrics society updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012; 60 (4): 616–31Google Scholar
  92. 92.
    Berdot S, Bertrand M, Dartigues JF, et al. Inappropriate medication use and risk of falls: a prospective study in a large community-dwelling elderly cohort. BMC Geriatr 2009; 9: 30. doi:10.1186/1471-2318-9–30PubMedGoogle Scholar
  93. 93.
    Gallagher P, Baeyens JP, Topinkova E, et al. Inter-rater reliability of STOPP (Screening Tool of Older Persons’ Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment) criteria amongst physicians in six European countries. Age Ageing 2009; 38 (5): 603–6PubMedGoogle Scholar
  94. 94.
    Gallagher P, O’Mahony D. STOPP (Screening Tool of Older Persons’ potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers’ criteria. Age Ageing 2008; 37 (6): 673–9PubMedGoogle Scholar
  95. 95.
    Gallagher P, Ryan C, Byrne S, et al. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment): consensus validation. Int J Clin Pharm Ther 2008; 46 (2): 72–83Google Scholar
  96. 96.
    Gallagher PF, O’Connor MN, O’Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/START criteria. Clin Pharmacol Ther 2011; 89 (6): 845–54PubMedGoogle Scholar
  97. 97.
    Hamilton H, Gallagher P, Ryan C, et al. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med 2011; 171 (11): 1013–9PubMedGoogle Scholar
  98. 98.
    Pyszka LL, Seys Ranola TM, Milhans SM. Identification of inappropriate prescribing in geriatrics at a Veterans Affairs hospital using STOPP/START screening tools. Consult Pharm 2010; 25 (6): 365–73PubMedGoogle Scholar
  99. 99.
    Pugh MJ, Hanlon JT, Wang CP, et al. Trends in use of high-risk medications for older veterans: 2004 to 2006. J Am Geriatr Soc 2011; 59 (10): 1891–8PubMedGoogle Scholar
  100. 100.
    Tinetti ME, Baker DI, King M, et al. Effect of dissemination of evidence in reducing injuries from falls. N Engl J Med 2008; 359 (3): 252–61PubMedGoogle Scholar
  101. 101.
    Rubenstein LZ, Powers CM, MacLean CH. Quality indicators for the management and prevention of falls and mobility problems in vulnerable elders. Ann Intern Med 2001; 135 (8 Pt 2): 686–93PubMedGoogle Scholar
  102. 102.
    Chang JT, Ganz DA. Quality indicators for falls and mobility problems in vulnerable elders. J Am Geriatr Soc 2007; 55 Suppl.: S327–34PubMedGoogle Scholar
  103. 103.
    Chang JT, Morton SC, Rubenstein LZ, et al. Interventions for the prevention of falls in older adults: systematic review and meta-analysis of randomised clinical trials. BMJ 2004; 328 (7441): 680PubMedGoogle Scholar
  104. 104.
    Shaw FE, Bond J, Richardson DA, et al. Multifactorial intervention after a fall in older people with cognitive impairment and dementia presenting to the accident and emergency department: randomised controlled trial. BMJ 2003; 326 (7380): 73PubMedGoogle Scholar
  105. 105.
    Coussement J, De PL, Schwendimann R, et al. Interventions for preventing falls in acute- and chronic-care hospitals: a systematic review and meta-analysis. J Am Geriatr Soc 2008; 56 (1): 29–36PubMedGoogle Scholar
  106. 106.
    Cumming RG, Sherrington C, Lord SR, et al. Cluster randomised trial of a targeted multifactorial intervention to prevent falls among older people in hospital. BMJ 2008; 336Google Scholar
  107. 107.
    Van der Velde N, Meerding WJ, Looman CW, et al. Cost effectiveness of withdrawal of fall-risk-increasing drugs in geriatric outpatients. Drugs Aging 2008; 25 (6): 521–9PubMedGoogle Scholar
  108. 108.
    Van der Velde N, Stricker BH, Pols HA, et al. Withdrawal of fall-risk-increasing drugs in older persons: effect on mobility test outcomes. Drugs Aging 2007; 24 (8): 691–9PubMedGoogle Scholar
  109. 109.
    Campbell AJ, Robertson MC, Gardner MM, et al. Psychotropic medication withdrawal and a home-based exercise program to prevent falls: a randomized, controlled trial. J Am Geriatr Soc 1999; 47 (7): 850–3PubMedGoogle Scholar
  110. 110.
    Hartholt K, Van der Velde N, Van Lieshout E, et al. [Cost]effectiveness of withdrawal of fall-risk increasing drugs versus conservative treatment in older fallers: design of a multicenter randomized controlled trial (IMPROveFALL-study). BMC Geriatr 2011; 11 (1): 48. doi:10.1186/1471-2318-11–48PubMedGoogle Scholar
  111. 111.
    Joester J, Vogler CM, Chang K, et al. Hypnosedative use and predictors of successful withdrawal in new patients attending a falls clinic: a retrospective, cohort study. Drugs Aging 2010; 27 (11): 915–24PubMedGoogle Scholar
  112. 112.
    Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs 2009; 23 (1): 19–34PubMedGoogle Scholar
  113. 113.
    Salonoja M, Salminen M, Aarnio P, et al. One-time counselling decreases the use of benzodiazepines and related drugs among community-dwelling older persons. Age Ageing 2010; 39 (3): 313–9PubMedGoogle Scholar
  114. 114.
    Smith AJ, Tett SE. Improving the use of benzodiazepines: is it possible? A non-systematic review of interventions tried in the last 20 years. BMC Health Serv Res 2010; 10: 321PubMedGoogle Scholar
  115. 115.
    Schiff GD, Galanter WL. Promoting more conservative prescribing. JAMA 2009; 301 (8): 865–7PubMedGoogle Scholar
  116. 116.
    Schiff GD, Rucker TD. Computerized prescribing: building the electronic infrastructure for better medication usage. JAMA 1998; 279 (13): 1024–9PubMedGoogle Scholar
  117. 117.
    Schnipper JL. Medication safety: are we there yet? Comment on “Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients”. Arch Intern Med 2011; 171 (11): 1019–20PubMedGoogle Scholar
  118. 118.
    Agostini JV, Zhang Y, Inouye SK. Use of a computer-based reminder to improve sedative-hypnotic prescribing in older hospitalized patients. J Am Geriatr Soc 2007; 55 (1): 43–8PubMedGoogle Scholar
  119. 119.
    Ball MJ, Lillis J. E-health: transforming the physician/patient relationship. Int J Med Inform 2001; 61 (1): 1–10PubMedGoogle Scholar
  120. 120.
    Dickerson S, Reinhart AM, Feeley TH, et al. Patient internet use for health information at three urban primary care clinics. J Am Med Inform Assoc 2004; 11 (6): 499–504PubMedGoogle Scholar
  121. 121.
    Weingart SN, Toth M, Sands DZ, et al. Physicians’ decisions to override computerized drug alerts in primary care. Arch Intern Med 2003; 163 (21): 2625–31PubMedGoogle Scholar
  122. 122.
    Tamblyn R, Huang A, Taylor L, et al. A randomized trial of the effectiveness of on-demand versus computer-triggered drug decision support in primary care. J Am Med Inform Assoc 2008; 15 (4): 430–8PubMedGoogle Scholar
  123. 123.
    van der Sijs H, Aarts J, Vulto A, et al. Overriding of drug safety alerts in computerized physician order entry. J Am Med Inform Assoc 2006; 13 (2): 138–47PubMedGoogle Scholar
  124. 124.
    Julien M, Hanley JA. Profile-specific survival estimates: making reports of clinical trials more patient-relevant. Clin Trials 2008; 5 (2): 107–15PubMedGoogle Scholar
  125. 125.
    Tamblyn RM, Eguale T, Buckeridge D, et al. The effectiveness of a new generation of computerized drug alerts in reducing the risk of injury from drug side effects: a cluster randomized trial. J Am Med Inform Assoc. Epub 2012 Jan 12. doi:10.1136/amiajnl-2011–000609Google Scholar
  126. 126.
    Hill S, Spink J, Cadilhac D, et al. Absolute risk representation in cardiovascular disease prevention: comprehension and preferences of health care consumers and general practitioners involved in a focus group study. BMC Public Health 2010; 10: 108PubMedGoogle Scholar
  127. 127.
    Edwards A, Elwyn G, Mulley A. Explaining risks: turning numerical data into meaningful pictures. BMJ 2002; 324 (7341): 827–30PubMedGoogle Scholar
  128. 128.
    Tzeng HM, Yin CY, Grunawalt J. Effective assessment of use of sitters by nurses in inpatient care settings. J Adv Nurs 2008; 64 (2): 176–83PubMedGoogle Scholar
  129. 129.
    Jaworowski S, Raveh D, Lobel E, et al. Constant observation in the general hospital: a review. Isr J Psychiatr Rel 2008; 45 (4): 278–84Google Scholar
  130. 130.
    Rausch DL, Bjorklund P. Decreasing the costs of constant observation. J Nurs Admin 2010; 40 (2): 75–81Google Scholar
  131. 131.
    Donoghue J, Graham J, Mitten-Lewis S, et al. A volunteer companion-observer intervention reduces falls on an acute aged care ward. Int J Health Care Qual Assur Inc Leadersh Health Serv 2005; 18 (1): 24–31PubMedGoogle Scholar
  132. 132.
    Worley LL, Kunkel EJ, Gitlin DF, et al. Constant observation practices in the general hospital setting: a national survey. Psychosomatics 2000; 41 (4): 301–10PubMedGoogle Scholar
  133. 133.
    Torkelson DJ, Dobal MT. Constant observation in medical-surgical settings: a multihospital study. Nurs Econ 1999; 17 (3): 149–55PubMedGoogle Scholar
  134. 134.
    Rochefort CM, Ward L, Ritchie JA, et al. Registered nurses’ job demands in relation to sitter use: nested case-control study. Nurs Res 2011; 60 (4): 221–30PubMedGoogle Scholar
  135. 135.
    Rochefort CM, Ward L, Ritchie JA, et al. Patient and nurse staffing characteristics associated with high sitter use costs. J Adv Nurs. Epub 2011 Nov 3. doi:10.1111/j.1365–2648.2011.05864.xGoogle Scholar
  136. 136.
    Charbonneau-Allard A-M, Fluet J, Lessard A, et al. Mécanismes pharmacologiques comme facteurs modifiables de la prescription de sitters. 2011. Montréal (QC): Faculte de pharmacie, Université de Montréal, 2011Google Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Allen R. Huang
    • 1
    • 4
  • Louise Mallet
    • 1
    • 2
  • Christian M. Rochefort
    • 3
  • Tewodros Eguale
    • 3
  • David L. Buckeridge
    • 3
  • Robyn Tamblyn
    • 3
  1. 1.Division of Geriatric MedicineMcGill UniversityMontrealCanada
  2. 2.Faculty of PharmacyUniversity of MontrealMontrealCanada
  3. 3.Division of Clinical EpidemiologyMcGill UniversityMontrealCanada
  4. 4.McGill University Health Centre, Royal Victoria HospitalMontréalCanada

Personalised recommendations